Affitech contracts with ProBioGen for producer cell line generation for oncology antibody candidate

13-Apr-2007

ProBioGen AG, and Affitech AS, jointly announced that they have entered into an agreement for a biopharmaceutical cell line to be developed by ProBioGen for high-level production of one of the lead candidates in Affitech's oncology therapeutic antibody pipeline.

Under the terms of the agreement, ProBioGen will apply its cell generation process for biopharmaceutical cell lines relying on the unique vectors and its pre-optimized CHO starter cell. This will be combined with automated cloning process to identify and develop a high producer line, which should be particularly suitable for a fed-batch development process. Financial details of the agreement have not been disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance